285 related articles for article (PubMed ID: 36265268)
21. Beta-secretase protein and activity are increased in the neocortex in Alzheimer disease.
Fukumoto H; Cheung BS; Hyman BT; Irizarry MC
Arch Neurol; 2002 Sep; 59(9):1381-9. PubMed ID: 12223024
[TBL] [Abstract][Full Text] [Related]
22. The beta-secretase, BACE: a prime drug target for Alzheimer's disease.
Vassar R
J Mol Neurosci; 2001 Oct; 17(2):157-70. PubMed ID: 11816789
[TBL] [Abstract][Full Text] [Related]
23. Glu11 site cleavage and N-terminally truncated A beta production upon BACE overexpression.
Liu K; Doms RW; Lee VM
Biochemistry; 2002 Mar; 41(9):3128-36. PubMed ID: 11863452
[TBL] [Abstract][Full Text] [Related]
24. Amyloid beta secretase gene (BACE) is neither mutated in nor associated with early-onset Alzheimer's disease.
Cruts M; Dermaut B; Rademakers R; Roks G; Van den Broeck M; Munteanu G; van Duijn CM; Van Broeckhoven C
Neurosci Lett; 2001 Nov; 313(1-2):105-7. PubMed ID: 11684351
[TBL] [Abstract][Full Text] [Related]
25. Failure of the interaction between presenilin 1 and the substrate of gamma-secretase to produce Abeta in insect cells.
Pitsi D; Kienlen-Campard P; Octave JN
J Neurochem; 2002 Oct; 83(2):390-9. PubMed ID: 12423249
[TBL] [Abstract][Full Text] [Related]
26. Partial reduction of amyloid β production by β-secretase inhibitors does not decrease synaptic transmission.
Satir TM; Agholme L; Karlsson A; Karlsson M; Karila P; Illes S; Bergström P; Zetterberg H
Alzheimers Res Ther; 2020 May; 12(1):63. PubMed ID: 32456694
[TBL] [Abstract][Full Text] [Related]
27. The physical approximation of APP and BACE-1: A key event in alzheimer's disease pathogenesis.
Sun J; Roy S
Dev Neurobiol; 2018 Mar; 78(3):340-347. PubMed ID: 29106038
[TBL] [Abstract][Full Text] [Related]
28. Proteolytic processing of the Alzheimer's disease amyloid precursor protein in brain and platelets.
Evin G; Zhu A; Holsinger RM; Masters CL; Li QX
J Neurosci Res; 2003 Nov; 74(3):386-92. PubMed ID: 14598315
[TBL] [Abstract][Full Text] [Related]
29. Potent BACE-1 inhibitor design using pharmacophore modeling, in silico screening and molecular docking studies.
John S; Thangapandian S; Sakkiah S; Lee KW
BMC Bioinformatics; 2011 Feb; 12 Suppl 1(Suppl 1):S28. PubMed ID: 21342558
[TBL] [Abstract][Full Text] [Related]
30. Targeting BACE with small inhibitory nucleic acids - a future for Alzheimer's disease therapy?
Nawrot B
Acta Biochim Pol; 2004; 51(2):431-44. PubMed ID: 15218540
[TBL] [Abstract][Full Text] [Related]
31. Degradation of BACE by the ubiquitin-proteasome pathway.
Qing H; Zhou W; Christensen MA; Sun X; Tong Y; Song W
FASEB J; 2004 Oct; 18(13):1571-3. PubMed ID: 15289451
[TBL] [Abstract][Full Text] [Related]
32. Dynamin 1 regulates amyloid generation through modulation of BACE-1.
Zhu L; Su M; Lucast L; Liu L; Netzer WJ; Gandy SE; Cai D
PLoS One; 2012; 7(9):e45033. PubMed ID: 23024787
[TBL] [Abstract][Full Text] [Related]
33. Reduced Aβ secretion by human neurons under conditions of strongly increased BACE activity.
Scholz D; Chernyshova Y; Ückert AK; Leist M
J Neurochem; 2018 Oct; 147(2):256-274. PubMed ID: 29804308
[TBL] [Abstract][Full Text] [Related]
34. Inhibiting β-secretase activity in Alzheimer's disease cell models with single-chain antibodies specifically targeting APP.
Boddapati S; Levites Y; Sierks MR
J Mol Biol; 2011 Jan; 405(2):436-47. PubMed ID: 21073877
[TBL] [Abstract][Full Text] [Related]
35. Uncovering gamma-secretase.
Steiner H
Curr Alzheimer Res; 2004 Aug; 1(3):175-81. PubMed ID: 15975065
[TBL] [Abstract][Full Text] [Related]
36. Progress toward the discovery and development of efficacious BACE inhibitors.
Durham TB; Shepherd TA
Curr Opin Drug Discov Devel; 2006 Nov; 9(6):776-91. PubMed ID: 17117686
[TBL] [Abstract][Full Text] [Related]
37. Beta-secretase inhibitors in phase I and phase II clinical trials for Alzheimer's disease.
Moussa CE
Expert Opin Investig Drugs; 2017 Oct; 26(10):1131-1136. PubMed ID: 28817311
[TBL] [Abstract][Full Text] [Related]
38. Alzheimer's-related endosome dysfunction in Down syndrome is Abeta-independent but requires APP and is reversed by BACE-1 inhibition.
Jiang Y; Mullaney KA; Peterhoff CM; Che S; Schmidt SD; Boyer-Boiteau A; Ginsberg SD; Cataldo AM; Mathews PM; Nixon RA
Proc Natl Acad Sci U S A; 2010 Jan; 107(4):1630-5. PubMed ID: 20080541
[TBL] [Abstract][Full Text] [Related]
39. Decrease in brain soluble amyloid precursor protein β (sAPPβ) in Alzheimer's disease cortex.
Wu G; Sankaranarayanan S; Hsieh SH; Simon AJ; Savage MJ
J Neurosci Res; 2011 Jun; 89(6):822-32. PubMed ID: 21433051
[TBL] [Abstract][Full Text] [Related]
40. The β-Secretase Enzyme BACE1: A Biochemical Enigma for Alzheimer's Disease.
Shah H; Patel A; Parikh V; Nagani A; Bhimani B; Shah U; Bambharoliya T
CNS Neurol Disord Drug Targets; 2020; 19(3):184-194. PubMed ID: 32452328
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
